India’s FY27 growth outlook has received upgrades from the OECD, Asian Development Bank, S&P Global Ratings and Fitch Ratings, with forecas...

Cupid Limited raised its FY27 guidance to Rs 725-750 crore revenue and Rs 210-225 crore net profit after strong June-quarter growth. Revenu...

Pre-budget meetings for the Union Budget 2027-28 will commence on October 12 and continue until November 13. These discussions aim to final...

The Asian Development Bank has raised its FY27 India growth forecast to 7% from 6.6%, citing strong public investment and resilience in ser...

The OECD has raised its FY27 India growth forecast by 80 basis points to 7.1%, from 6.3% earlier, joining Fitch, S&P Global Ratings and Moo...

India’s 7.8% growth has the world taking notice. Fitch, S&P and Moody’s have all raised their forecasts, even as questions over the GDP num...

India's economy is demonstrating resilience, leading to raised growth forecasts from institutions like the Asian Development Bank. However,...

S&P Global Ratings has upgraded its forecast for India's real GDP growth to 7% for the FY27. Strong industrial activity, healthy consumptio...

India's economy may slow in the second half of fiscal 2027. Tighter financial conditions and higher energy prices will impact economic acti...

UBS has raised its Meesho estimates across NMV, contribution profit and EBITDA, citing stronger seller and buyer growth and improving unit ...

Sansera Engineering shares rallied after Goldman Sachs raised its target price to Rs 4,990 from Rs 4,500 while retaining its Buy rating. Th...

Ichor Biologics is seeking eighty to one hundred million dollars from private equity investors. The Hyderabad-based company operates in the...

Moody's Ratings increased India's economic growth forecast for fiscal year 2027 to seven percent. The agency cited the nation's resilience ...

Jefferies has retained its Buy rating on Navin Fluorine International and raised its price target to Rs 9,405, citing growth prospects in C...

Moody's has raised India's GDP growth forecast to seven percent for 2026-27. Strong private consumption and robust investment are driving t...

Amid the backdrop of increasing US interest rates in August, fund managers proceeded with caution, prioritizing large-cap stocks that offer...

JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The bro...